Skip to main content
. 2017 Jan 28;4(2):ofx012. doi: 10.1093/ofid/ofx012

Table 4.

Risk Factors for Liver Aminotransferases >200 U/L and Severe Acute Liver Injury Among HIV-Infected Individuals Who Were New Initiators of Antiretroviral Therapy Within Kaiser Permanente Northern California (2004–2010) and the Veterans Aging Cohort Study (2004–2012)

Characteristic Unadjusted HR of Liver Aminotransferases >200 U/L (95% CI) Adjusted HRa of Liver Aminotransferases >200 U/L (95% CI) Unadjusted HRb of Severe ALI (95% CI)
Age
18–50 years Reference Reference Reference
≥50 years 1.25 (0.95–1.64) 0.89 (0.66–1.19) 2.66 (1.25–5.69)
Sex
Male Reference Reference Reference
Female 0.87 (0.45–1.70) 1.11 (0.56–2.21) 2.10 (0.64–6.93)
Race
Non-Black Reference Reference Reference
Black 1.17 (0.89–1.53) 0.88 (0.66–1.19) 1.44 (0.70–2.96)
Body Mass Index
<30 kg/m2 Reference Reference Reference
≥30 kg/m2 0.92 (0.64–1.32) 0.93 (0.64–1.35) 0.90 (0.34–2.35)
Viral Hepatitis Coinfection
Uninfected Reference Reference Reference
HCV or HBV-infected 5.26 (4.00–6.93) 4.21 (3.10–5.72) 4.64 (2.26–9.51)
History of Alcohol Dependence/Abuse
No Reference Reference Reference
Yes 1.63 (1.22–2.19) 1.10 (0.81–1.50) 1.47 (0.67–3.20)
Diabetes Mellitus
No Reference Reference Reference
Yes 1.46 (0.97–2.21) 1.22 (0.80–1.87) 2.00 (0.77–5.23)
Heart Failure
No Reference Reference Reference
Yes 0.86 (0.27–2.68) 0.76 (0.24–2.42) 6.26 (1.90–20.66)
HIV RNA (per log10 copies/mL) 0.95 (0.80–1.12) 0.90 (0.75–1.08) 1.82 (1.10–3.01)
CD4 cell count
≥500 cells/mm3 Reference Reference Reference
200–500 cells/mm3 1.39 (0.78–2.48) 1.38 (0.76–2.48) 0.65 (0.14–3.14)
<200 cells/mm3 1.73 (0.96–3.10) 1.68 (0.91–3.10) 2.62 (0.61–11.16)
Baseline ALT
ALT <40 IU/mL Reference Reference Reference
ALT ≥40 IU/mL 3.38 (2.55–4.49) 2.49 (1.85–3.34) 1.92 (0.93–3.96)

Abbreviations: ALI, acute liver injury; ALT, alanine aminotransferase; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HR, hazard ratio; RNA, ribonucleic acid.

aModel adjusted for all covariates shown as well as calendar year of antiretroviral therapy initiation and data source.

bDue to the low number of severe ALI events, adjusted analyses could not be performed.